Insulin Zinc Suspension (Lente/Ultralente) for Type 1 Diabetes
Mechanism of Action
Insulin zinc suspension consists of insulin crystals complexed with zinc in a neutral-pH buffer. After subcutaneous injection, the crystals dissolve slowly, providing a prolonged, peakless insulin release over 24–48 hours (ultralente) or 12–24 hours (lente).
Pharmacokinetics
- Onset: 2–4 hours
- Peak: minimal (ultralente) or 8–12 hours (lente)
- Duration: up to 24–36 hours (ultralente), 18–24 hours (lente)
Clinical Use
- Basal insulin coverage in type 1 diabetes (often combined with rapid-acting analogs for meals).
- Dosing individualized; typically once or twice daily.
- Requires consistent timing; monitor for hypoglycemia, especially overnight.
Note
Lente and ultralente formulations have largely been replaced by long-acting analogs (glargine, detemir, degludec) which offer more predictable profiles. However, zinc suspensions remain an option where analogs are unavailable or unaffordable.
Diabetes - Related Articles
- Ketoacidosis: Causes, Symptoms, and Emergency Treatment
- Diabetic Foot Care: A Comprehensive Guide to Prevention & Treatment
- Diabetes Management: Essential Care & Monitoring Tips
- Gestational Diabetes Treatment: Medications & Management
- Manage Blood Sugar: A Comprehensive Guide to Healthy Levels
- Insulin Therapy: Understanding Potential Complications & Risks
- Understanding Type 1 Diabetes: Causes, Symptoms & Risk Factors
